BackPrecision Biosciences Overview

Precision Biosciences Receivables

Latest receivables for DTIL: $4M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$4.00M
99900.00% YoYΔ $4.00M vs prior year quarter

Peer average

Loading

Precision Biosciences Receivables History

Loading

Precision Biosciences vs. peers: Receivables Comparison

Loading

Precision Biosciences Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Precision Biosciences (DTIL) FAQ

As of the most recent data (March 2026), DTIL shows a receivables of $4M. That compares with $4K in the prior-year period — up 99900.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, DTIL's receivables is now $4M (was $4K) — a 99900.0% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Precision Biosciences is outperforming or lagging.

Tracking DTIL's receivables over time shows whether Precision Biosciences is scaling, shrinking, or reshaping that part of the business. The current reading is $4M That compares with $4K in the prior-year period — up 99900.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Precision Biosciences's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $4M) with ownership activity and broader fundamentals.

Precision Biosciences's receivables is $4M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.